13F filerCIK 1536411 ↗

Duquesne Family Office

You are looking at Q4 2025. See the latest, Q3 2026 →

Reported value

$4.49B

+11% on the quarter before

Positions

62

28 new, 31 sold out

Top 10

52.3%

of the value

Est. gain

+$316.2M

on stocks held all quarter

Est. return

+14.2%

on those stocks since Q3 2025

Filed

Feb 17, 2026

On SEC EDGAR ↗

Positions as of Dec 31, 2025, from Duquesne Family Office's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2025. Striped tiles are options.

38 others21%
Natera Inc13%
Select Sector SPDR Tr6.7%
Insmed Inc5.7%
Invesco Exchange Traded Fd T5.0%
Teva Pharmaceutical Inds Ltd4.1%
Woodward Inc4.0%
Amazon3.8%TSMC3.7%
Coupang Inc3.6%
Ishares IncCALL3.0%
Alphabet2.7%Sea2.7%
Ishares Inc2.5%
Newamsterdam Pharma Company2.4%
MercadoLibre2.1%
Bbb Foods Inc2.0%
Restaurant Brands Intl Inc1.8%
Cogent Biosciences Inc1.8%
Alcoa Corp1.6%
Entegris1.6%DocuSign1.6%Lattice Semiconductor1.5%Bloom Energy1.4%
Wabtec1.4%

Largest buys

Since Q3 2025, sized at quarter-end prices.

  1. Select Sector SPDR Tr~$301.0MNew, 0.0% → 6.7% of the portfolio+5,495,600 shares
  2. Invesco Exchange Traded Fd T~$224.9MNew, 0.0% → 5.0% of the portfolio+1,173,925 shares
  3. Ishares IncCALL~$134.3MNew, 0.0% → 3.0% of the portfolio+4,228,000 underlying
  4. Ishares Inc~$112.9MNew, 0.0% → 2.5% of the portfolio+3,552,575 shares
  5. Alphabet~$88.5MAdded, 0.6% → 2.7% of the portfolio+282,800 shares
  6. Sea~$85.5MAdded, 1.2% → 2.7% of the portfolio+669,920 shares
  7. Alcoa Corp~$73.1MNew, 0.0% → 1.6% of the portfolio+1,376,050 shares
  8. Entegris~$71.1MNew, 0.0% → 1.6% of the portfolio+844,160 shares
  9. Amazon~$69.4MAdded, 2.4% → 3.8% of the portfolio+300,870 shares
  10. Lattice Semiconductor~$68.1MNew, 0.0% → 1.5% of the portfolio+925,970 shares

Largest sells

Since Q3 2025, sized at quarter-end prices.

  1. Teva Pharmaceutical Inds Ltd~$334.5MCut, 8.3% → 4.1% of the portfolio−10,719,065 shares
  2. Insmed Inc~$163.9MCut, 8.6% → 5.7% of the portfolio−941,683 shares
  3. Natera Inc~$161.1MCut, 12.7% → 12.8% of the portfolio−703,175 shares
  4. Verona Pharma Plc~$106.9MSold out, 2.6% → 0.0% of the portfolio−1,002,080 shares
  5. TSMC~$67.5MCut, 5.3% → 3.7% of the portfolio−222,000 shares
  6. Meta~$55.9MSold out, 1.4% → 0.0% of the portfolio−76,100 shares
  7. Ishares Tr~$54.6MCut, 2.5% → 1.1% of the portfolio−997,500 shares
  8. Carpenter Technology Corp~$54.0MSold out, 1.3% → 0.0% of the portfolio−220,035 shares
  9. Citigroup Inc~$52.3MSold out, 1.3% → 0.0% of the portfolio−514,850 shares
  10. Twilio~$51.3MSold out, 1.3% → 0.0% of the portfolio−512,800 shares

Holdings

As of Dec 31, 2025; changes in shares since Sep 30, 2025.

Positions, sorted by share of the portfolio
HoldingValue
Natera IncCOM · shares −22% · price +42.3%12.8%$575.3M+$171.1M
Select Sector SPDR TrSTATE STREET FIN · shares New6.7%$301.0M—
Insmed IncCOM PAR $.01 · shares −39% · price +20.9%5.7%$257.9M+$44.5M
Invesco Exchange Traded Fd TS&P500 EQL WGT · shares New5.0%$224.9M—
Teva Pharmaceutical Inds LtdSPONSORED ADS · shares −65% · price +54.5%4.1%$183.4M+$64.7M
Woodward IncCOM · shares −6.6% · price +19.6%4.0%$178.7M+$29.3M
AmazonCOM · shares +69% · price +5.1%3.8%$170.3M+$4.9M
TSMCSPONSORED ADS · shares −29% · price +8.8%3.7%$165.0M+$13.4M
Coupang IncCL A · shares +46% · price −26.7%3.6%$159.8M−$39.9M
Ishares IncCALLMSCI BRAZIL ETF · shares New3.0%$134.3M—
AlphabetCAP STK CL A · shares +277% · price +28.8%2.7%$120.5M+$7.1M
SeaSPONSORD ADS · shares +244% · price −28.6%2.7%$120.4M−$14.0M
Ishares IncMSCI BRAZIL ETF · shares New2.5%$112.9M—
Newamsterdam Pharma CompanyORDINARY SHARES · shares +60% · price +23.3%2.4%$107.7M+$12.8M
MercadoLibreCOM · shares −19% · price −13.8%2.1%$95.0M−$15.2M
Bbb Foods IncCL A COM · shares +126% · price +23.8%2.0%$89.3M+$7.6M
Restaurant Brands Intl IncCOM · shares +6.9% · price +6.4%1.8%$82.5M+$4.6M
Cogent Biosciences IncCOM · shares +109% · price +147.3%1.8%$78.7M+$22.4M
Alcoa CorpCOM · shares New1.6%$73.1M—
EntegrisCOM · shares New1.6%$71.1M—
DocuSignCOM · shares −40% · price −5.1%1.6%$69.7M−$3.8M
Lattice SemiconductorCOM · shares New1.5%$68.1M—
Bloom EnergyCOM CL A · shares New1.4%$64.3M—
WabtecCOM · shares −0.8% · price +6.5%1.4%$64.1M+$3.9M
Roku IncCOM CL A · shares −29% · price +8.4%1.4%$63.2M+$4.9M
Total 62 positions100%$4.49B+$316.2M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q3 2025 to Q4 2025: 32 stocks held throughout, up $316.2M (+14.2%).

  1. Natera Inc+$171.1M+42%
  2. Teva Pharmaceutical Inds Ltd+$64.7M+55%
  3. Insmed Inc+$44.5M+21%
  4. Woodward Inc+$29.3M+20%
  5. Cogent Biosciences Inc+$22.4M+147%
  6. Stubhub Hldgs Inc−$7.6M−20%
  7. Purecycle Technologies Inc−$10.5M−35%
  8. Sea−$14.0M−29%
  9. MercadoLibre−$15.2M−14%
  10. Coupang Inc−$39.9M−27%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$6.00B$3.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$4.47B−14%SEC ↗
Q2 2026$5.21B+54%SEC ↗
Q1 2026$3.38B−25%SEC ↗
Q4 2025$4.49B+11%SEC ↗
Q3 2025$4.06B−0%SEC ↗
Q2 2025$4.07B+33%SEC ↗
Q1 2025$3.06B−18%SEC ↗
Q4 2024$3.72B+26%SEC ↗
Q3 2024$2.95B+1%SEC ↗
Q2 2024$2.92B−34%SEC ↗
Q1 2024$4.39B+31%SEC ↗
Q4 2023$3.35B+20%SEC ↗
Q3 2023$2.79B−3%SEC ↗
Q2 2023$2.87B+25%SEC ↗
Q1 2023$2.31B+14%SEC ↗
Q4 2022$2.02B+15%SEC ↗
Q3 2022$1.76B+28%SEC ↗
Q2 2022$1.38B−40%SEC ↗
Q1 2022$2.31B−16%SEC ↗
Q4 2021$2.76B−10%SEC ↗
Q3 2021$3.08B−24%SEC ↗
Q2 2021$4.04B−11%SEC ↗
Q1 2021$4.53B+22%SEC ↗
Q4 2020$3.71B+8%SEC ↗
Q3 2020$3.44B+5%SEC ↗
Q2 2020$3.27B+32%SEC ↗
Q1 2020$2.47B−28%SEC ↗
Q4 2019$3.41B+33%SEC ↗
Q3 2019$2.57B−24%SEC ↗
Q2 2019$3.37B−2%SEC ↗
Q1 2019$3.45B+100%SEC ↗
Q4 2018$1.73B−18%SEC ↗
Q3 2018$2.10B+2%SEC ↗
Q2 2018$2.07B+14%SEC ↗
Q1 2018$1.81B−9%SEC ↗
Q4 2017$1.98B−10%SEC ↗
Q3 2017$2.20B+18%SEC ↗
Q2 2017$1.87B+22%SEC ↗
Q1 2017$1.52B+49%SEC ↗
Q4 2016$1.03B−9%SEC ↗
Q3 2016$1.13B+30%SEC ↗
Q2 2016$870.7M−35%SEC ↗
Q1 2016$1.34BSEC ↗

Subscribe to TheInference for free